More Time for Women Regardless of BRCA Mutation Status
ZEJULA is the first and only once-daily PARP inhibitor for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.1-3
The primary end point of the pivotal trial was PFS from time of randomization to time of disease progression or death. At the time of the PFS analysis, limited overall survival data were available, with 17% of planned survival events occurring in the study (HR=0.73; 95% CI, 0.48-1.13), P=0.15.1,4,5
Median PFS in the pivotal trial:
BRCA, breast cancer susceptibility gene; CI, confidence interval; gBRCAmut, germline BRCA mutated; HR, hazard ratio; non-gBRCAmut, not germline BRCA mutated; PARP, poly(ADP-ribose) polymerase; PFS, progression-free survival.